The startup specializes in cell-free liquid biopsy technology that enables minimally-invasive molecular diagnostics for oncology. This approach facilitates early cancer detection, treatment selection, and therapy monitoring through comprehensive big data analysis.
Funding
$50.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional methods for cancer diagnostics, treatment selection, and therapy monitoring often rely on invasive tissue biopsies, which pose risks to patients and may not always capture the full heterogeneity of the tumor. The need for less invasive and more comprehensive molecular profiling techniques is critical for improving cancer management.
Solution
Predicine offers a cell-free liquid biopsy platform that enables minimally invasive molecular diagnostics for oncology, leveraging both blood and urine samples. The platform analyzes cell-free circulating DNA and RNA to provide comprehensive genomic and transcriptomic profiling of tumors. By integrating advanced next-generation sequencing (NGS) and AI-driven bioinformatics, Predicine delivers actionable insights for early cancer detection, treatment selection, disease monitoring, and minimal residual disease (MRD) assessment. The GeneRADAR platform measures cancer-associated genomic blueprints (DNA) and functional biology (RNA) in a single tube of blood or urine, providing accurate and in-depth insights.
Target Audience
Predicine's primary customers include biopharmaceutical companies, clinical researchers, and healthcare providers involved in oncology drug development, clinical trials, and precision medicine initiatives.
Features
- Proprietary GeneRADAR platform for simultaneous profiling of cell-free DNA and RNA from blood or urine
- Comprehensive genomic profiling assays, including PredicineATLAS™ (600 genes), PredicineCARE™ (152 genes), and PredicineRNA™ (88 genes)
- Urine-based liquid biopsy for robust variant detection, particularly in genitourinary cancers
- DeepSEA machine learning platform for ultra-sensitive cancer detection, navigating genetic noise to reveal meaningful biological data
- Harmonized assays supported by unified quality management systems and workflow in CLIA-certified and CAP-accredited laboratories in both the U.S. and China
- Services for biopharma clinical research, supporting biomarker-driven drug development from target discovery to CDx development
- Minimal residual disease (MRD) detection assays, including PredicineBEACON™, for personalized monitoring of treatment response and recurrence
- Whole exome sequencing (WES) capabilities for comprehensive genomic analysis